Alumis (ALMS) Competitors $5.11 -0.28 (-5.19%) Closing price 04:00 PM EasternExtended Trading$5.11 0.00 (-0.02%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. ADPT, AMPH, EVO, OCUL, BGM, IOVA, AUPH, ARDX, SNDX, and GPCRShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Adaptive Biotechnologies (ADPT), Amphastar Pharmaceuticals (AMPH), Evotec (EVO), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Iovance Biotherapeutics (IOVA), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Syndax Pharmaceuticals (SNDX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Adaptive Biotechnologies Amphastar Pharmaceuticals Evotec Ocular Therapeutix Qilian International Holding Group Iovance Biotherapeutics Aurinia Pharmaceuticals Ardelyx Syndax Pharmaceuticals Structure Therapeutics Alumis (NASDAQ:ALMS) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings. Do institutionals & insiders have more ownership in ALMS or ADPT? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, ALMS or ADPT? Alumis has higher earnings, but lower revenue than Adaptive Biotechnologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/AN/AN/AN/AAdaptive Biotechnologies$178.96M6.43-$159.49M-$1.09-7.10 Is ALMS or ADPT more profitable? Alumis has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -89.12%. Alumis' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A N/A N/A Adaptive Biotechnologies -89.12%-64.65%-26.45% Does the MarketBeat Community believe in ALMS or ADPT? Adaptive Biotechnologies received 78 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 57.99% of users gave Adaptive Biotechnologies an outperform vote. CompanyUnderperformOutperformAlumisOutperform Votes20100.00% Underperform VotesNo VotesAdaptive BiotechnologiesOutperform Votes9857.99% Underperform Votes7142.01% Does the media prefer ALMS or ADPT? In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Alumis. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 6 mentions for Alumis. Adaptive Biotechnologies' average media sentiment score of 1.02 beat Alumis' score of 0.61 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ALMS or ADPT? Alumis currently has a consensus target price of $26.00, suggesting a potential upside of 408.81%. Adaptive Biotechnologies has a consensus target price of $9.40, suggesting a potential upside of 21.45%. Given Alumis' stronger consensus rating and higher possible upside, research analysts plainly believe Alumis is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Adaptive Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAlumis beats Adaptive Biotechnologies on 8 of the 14 factors compared between the two stocks. Remove Ads Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$241.30M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E RatioN/A6.7921.7317.81Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / BookN/A5.866.464.00Net IncomeN/A$141.86M$3.20B$247.23M7 Day Performance-30.95%8.98%6.54%7.26%1 Month Performance11.82%-12.65%-8.55%-6.26%1 Year PerformanceN/A-11.99%10.33%-0.18% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.4159 of 5 stars$5.11-5.2%$26.00+408.8%N/A$241.30MN/A0.00N/AADPTAdaptive Biotechnologies3.2591 of 5 stars$7.58-1.9%$9.40+23.9%+159.8%$1.13B$178.96M-6.95790Positive NewsAMPHAmphastar Pharmaceuticals4.2953 of 5 stars$23.40-0.5%$43.50+85.9%-38.4%$1.12B$731.97M7.831,620News CoveragePositive NewsEVOEvotec1.4337 of 5 stars$3.07+0.3%$5.93+93.3%-54.7%$1.09B$777.05M0.004,200Upcoming EarningsGap UpOCULOcular Therapeutix3.4204 of 5 stars$6.51+1.6%$16.38+151.5%-5.3%$1.04B$63.72M-4.95230BGMQilian International Holding GroupN/A$10.57-2.5%N/AN/A$1.03B$25.10M0.00298Positive NewsIOVAIovance Biotherapeutics4.2358 of 5 stars$3.13+2.1%$20.25+548.0%-72.4%$1.02B$164.07M-2.10500Analyst ForecastNews CoverageAUPHAurinia Pharmaceuticals2.5666 of 5 stars$7.37+0.3%$11.50+56.1%+51.6%$1.01B$235.13M-49.16300News CoverageGap DownARDXArdelyx4.2132 of 5 stars$4.22-0.8%$10.61+151.7%-35.3%$1.01B$333.62M-26.5390SNDXSyndax Pharmaceuticals3.4858 of 5 stars$10.30-2.1%$36.20+251.6%-48.3%$893.40M$23.68M-2.86110Gap DownGPCRStructure Therapeutics2.5757 of 5 stars$15.39+2.2%$81.29+428.3%-51.8%$882.22MN/A-20.79136News Coverage Remove Ads Related Companies and Tools Related Companies ADPT Alternatives AMPH Alternatives EVO Alternatives OCUL Alternatives BGM Alternatives IOVA Alternatives AUPH Alternatives ARDX Alternatives SNDX Alternatives GPCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
